Dosing: Adult; 15 mg/kg /Day max of 1.5 g daily, in 2 to 4 divided doses. The same doses may be given by intravenous infusion of a 0.25 to 0.5% solution over 30 to 60 minutes.
Note: Dosing should be based on ideal body weight
Susceptible systemic infections: I.M., I.V.: 5-7.5 mg/kg/dose in divided doses every 8-12 hours (<15 mg/kg/day)
Following surgical contamination, peritonitis: Intraperitoneal: 500 mg
Irrigating solution: 0.25%; maximum 1.5 g/day (via all administration routes)
Aerosol: 250 mg 2-4 times/day
Dosing: Pediatric
Note: Dosing should be based on ideal body weight
Infections: I.M., I.V.: 15 mg/kg/day in divided doses every 8-12 hours
Dosing: Geriatric
I.M., I.V.: Initial dose should be 5-7.5 mg/kg based on ideal body weight (except in obese patients); maintenance dose and interval should be adjusted for estimated renal function; dosing interval in most older patients is every 12-24 hours (see Dosing in Renal Impairment).
Dosing: Renal Impairment
Clcr 50-80 mL/minute: Administer 60% to 90% of dose or administer every 8-12 hours.
Clcr 10-50 mL/minute: Administer 30% to 70% of dose or administer every 12 hours.
Clcr <10 mL/minute: Administer 20% to 30% of dose or administer every 24-48 hours
Kanamycin Brands
| Brand Name | Manufacturer Name | Distributor | Drug Strength | Packaging | Formulation | Formulation Strength | Price |
|---|---|---|---|---|---|---|---|
| Dawa-cin | Dawa Limited | Dawa Limited | 1000mg | 1 | Injection | KES 18.00 |
| Kanamycin more info | |
|---|---|
| Mode Of Action | irreversibly binds to 30s sub-unit of bacterial ribosomes; blocks recognition step in protein synthesis and causes growth inhibition. |
| Drug Indication | Gram negative infections (when less toxic antibiotics are unsuitable). |
| Precautions | Avoid use with potent diuretics, nephrotoxic and neurotoxic drugs, impaired renal functions, myasthenia gravis. |
| Contra-Indications | Pregnancy and lactation, myasthenia gravis |
| Side Effects | Vestibular and auditory damage, nephrotoxicity; rarely, hypomagnesaemia on prolonged therapy, antibiotic-associated colitis, stomatitis; also reported, nausea, vomiting, rash, blood disorders. |
| Dosage | By intramuscular injection, and in acute infections adults may be given 15 mg/kg daily, to a maximum of 1.5 g daily, in 2 to 4 divided doses. The same doses may be given by intravenous infusion of a 0.25 to 0.5% solution over 30 to 60 minutes. |
| Pregnancy Category | Category D |
| Pregnancy Category Description | Drugs, which have caused, are suspected to have caused, or may be expected to cause an increased rise in the frequency of malformations or irreversible damage. These drugs may also have adverse pharmacological effects required required |
| Drug Category | DRUGS ACTING ON INFECTIONS |
| Drug Sub-Category | Aminoglycosides |